Notably, we did not find that the presence of FLT3-ITD to be predictive of the likelihood of either response or overall survival which diverges from the experience of the PETHEMA group with FLAG-IDA and of the GOELAMS study group which studied outcomes of R/R AML patients with various salvage regimens with combined gemtuzumab ozogamicin [42, 43]. This evidence concerns the gene FLT3 and acute myeloid leukemia.